Schedule 13G ownership disclosure
Syndax Pharmaceuticals Inc
Common Stock · CUSIP: 87164F105
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Morgan Stanley
Shares: 2,040,013 · Class: 2.4%
- Morgan Stanley & Co. LLC
Shares: 213,174 · Class: 0.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000895421-25-000369
- Form type
- SCHEDULE 13G/A
- Filer
- MORGAN STANLEY
- CIK
- CIK 895421
- Filed
- May 07, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership